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KESAN-KESAN EKSTRAK AKUES Catharanthus roseus KE ATAS SEL 
JURKAT DAN SEL DARAH PERIFERAL MONONUKLEAR NORMAL 
 
ABSTRAK 
Objektif utama kajian terbaharu ini ialah untuk menilai kesan-kesan ekstrak akues daun 
C.roseus ke atas sel Jurkat (T-sel leukemik) dan sel darah periferal mononuklear normal. 
Analitikal kromatografi cecair prestasi tinggi (HPLC) telah digunakan untuk 
mendapatkan kepekatan vinblastine dalam ekstrak C.roseus manakala pengenalpastian 
sebatian terpilih telah ditentukan dengan membandingkan spektrum UV setiap kompaun 
dengan standard sebatian yang sebelum ini dikenal pasti dalam C.roseus. Data analisis 
menunjukkan kepekatan vinblastine adalah 1636 ± 0.2 µg g-1 ekstrak akueus, bersamaan 
dengan 445.6 ± 0.06 µg g-1 mg daun kering. Selain itu, empat alkaloid telah dikenal pasti 
sebagai serpentine, vindoline, catharanthine dan vindoline. 
Kesan-kesan toksik ekstrak ke atas sel Jurkat dan sel darah periferal mononuklear 
normal telah ditentukan menerusi MTS [3-(4,5-dimethylthiazol-2-yl)-5(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Ekstrak C.roseus 
telah merencat pertumbuhan sel Jurkat secara ketara, tetapi juga telah merangsang 
pertumbuhan sel mononuklear normal. Kesan toksik ke atas sel Jurkat telah ditunjukkan 
dengan nilai-nilai kepekatan rencatan separuh maksimum (IC50) 2.55 µg/ml dan 2.38 
µg/ml, masing-masing pada 48 dan 72 jam. Pertumbuhan maksimal sel darah periferal 
mononuklear normal didapati apabila diubati dengan kepekatan 1000 µg/ml ekstrak 
C.roseus pada masa pengeraman pelbagai untuk penderma darah yang berbeza. 
 xv 
Analisa aliran sitometri mendedahkan bahawa ekstak C.roseus telah menyebabkan 
perencatan fasa S ke atas sel Jurkat manakala induksi apoptosis telah disahkan oleh 
pengesanan fragmentasi DNA dan perubahan phosphatidylserine dalam cara yang 
bergantung kepada masa. 
Penilaian caspase 3/7, pembebasan cytochrome c dan potensi membran mitokondria 
(MMP) mendedahkan mekanisma apoptosis sel Jurkat yang dirawat oleh C.roseus 
ekstrak adalah melalui laluan mitokondria yang melibatkan pembebasan cytochrome c 
dari mitokondria ke cytosol dan pengaktifan caspase 3/7. Pembebasan cytochrome c 
telah dikaitkan dengan kekurangan MMP.  
Ungkapan gen berkaitan onkologi manusia telah ditayangkan dengan menggunakan 
pemprosesan tinggi RT-PCR teknik. Analisis gen ungkapan sel Jurkat yang dirawat oleh 
C.roseus ekstrak menunjukkan bahawa 36 gen kebezaan selia gen daripada 1023 gen. 
Daripada jumlah ini, 20 gen telah meningkat dan 16 menurun ekspresi. Gen kebezaan 
terlibat dalam apoptosis dan kitaran sel.  
Kesan proliferatif pada sel darah periferal mononuklear normal yang dirawat oleh 
ekstrak C.roseus terus dinilai dengan imunofenotip menggunakan antibodi monoklonal 
terpilih dan diikuti oleh pengukuran kuantitatif komplemen (C3, C4) dan 
immunoglobulin (IgG, IgA, IgM). Induksi proliferasi sel boleh diperhatikan terutamanya 
CD4+, menghasilkan nisbah CD4/CD8 yang lebih tinggi berbanding dengan kawalan. 
Penghasilan ketara bagi IgG, IgA dan C3 telah didokumenkan. 
Data-data ini menunjukkan bahawa ekstrak akues C.roseus menunjukkan kesan yang 
terpilih antara sel-sel normal dan Jurkat. Ini menunjukkan potensi kegunaannya sebagai 
 xvi 
rawatan leukemik dan pembantu tambahan di mana imun aktiviti telah ditindas semasa 
kemoterapi. 
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EFFECTS OF Catharanthus roseus AQUEOUS EXTRACT ON JURKAT CELLS 
AND NORMAL PERIPHERAL BLOOD MONONUCLEAR CELLS 
 
ABSTRACT 
 
The objective of the present study was to evaluate the effects of crude aqueous extract of 
C.roseus leaves on Jurkat cell line (leukemic T-cells) and normal peripheral blood 
mononuclear cells (PBMCs). 
Analytical high performance liquid chromatography (HPLC) was used to obtain the 
concentration of vinblastine in the C.roseus extract while the identification of selective 
compounds was determined by comparing the UV spectra of each compound with 
standards of compounds previously identified in C.roseus. The analytical data indicated 
the concentration of vinblastine was 1636 ± 0.2 µg g-1 of aqueous extract, equivalent to 
445.6 ± 0.06 µg g-1 of dried leaves. Additionally, four of the alkaloids were identified as 
serpentine, vindoline, catharanthine and vindoline.  
The cytotoxicity effects of the extract on Jurkat cells and normal PBMCs were first 
examined by MTS [3-(4,5-dimethylthiazol-2-yl)-5(3- carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] assay. The C.roseus extract was found significantly 
inhibited the proliferation of the Jurkat cells and also induced the proliferation of normal 
PBMCs. The cytotoxicity effect on Jurkat cells was demonstrated with IC50 values of 
2.55 µg/ml and 2.38 µg/ml at 48 h and 72 h, respectively. Maximal cell proliferation was 
observed in PBMCs incubated with 1000 µg/ml of the C.roseus extract at various 
incubation times for different blood donor.  
 xviii 
Flow cytometry analysis revealed that the C.roseus extract caused S-phase Jurkat cells 
arrest while induction of apoptosis was confirmed by the detection of DNA 
fragmentation and translocated phosphatidylserine in a time-dependent manner. 
Examination of the caspase 3/7, cytochrome c release and mitochondrial membrane 
potential (MMP) revealed apoptosis mechanism in C.roseus-treated Jurkat cells was 
mediated via mitochondrial pathway involving the release of cytochrome c from 
mitochondria to cytosol and activation of caspase 3/7. The cytochrome c release was 
correlated with the depletion of MMP.  
The expression of human oncology-related genes was screened by using high throughput 
RT-PCR technique. The gene expression analysis of the C.roseus-treated Jurkat cells 
showed that 36 genes were differentially expressed out of 1023 genes. Of these, 20 
genes were upregulated and 16 were downregulated. The differentially expressed genes 
were involved in apoptosis and cell cycle progression.  
The proliferative effects on normal PBMCs treated with the C.roseus extract were 
further assessed by immunophenotyping using selective monoclonal antibodies followed 
by quantitative measurement of complements (C3, C4) and immunoglobulins (IgG, IgA, 
IgM). The induction of the cell proliferation could be observed especially CD4+, 
indicating higher CD4/CD8 ratio as compared to control. A significant production of 
IgG, IgA and C3 was documented. 
These data indicated that the C.roseus extract showed selective effects between normal 
and Jurkat cells, suggesting its potential use as leukemic treatment and adjuvant 
supplement, whose immune activities were suppressed during chemotherapies.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Research Background 
Leukemia is one of the most common cancers in the world (Agostini et al., 
2011). A report provided by the International Agency for Research on Cancer 
(IARC) stated that in 2008, leukemia has been listed as amongst the top fifteen most 
common cancers in the world, contributing to 2.8% of incidence rate and 3.4% of 
mortality rate for all cancer types, in both men and women. In Malaysia, this disease 
has been listed as the tenth commonest cancer, with 4.3% incidence rate and 5.8% 
mortality rate in both sexes. According to the cancer statistic reported by 
Surveillance Epidemiology and End Result (SEER), National Cancer Institute, it is 
estimated that 26,830 men and 20,320 women from the United State population that 
will be diagnosed with leukemia and 23,540 men and women will die of leukemia in 
2012, equivalent of 1 in 74 men and women will be diagnosed with leukemia during 
their lifetime (Howlader et al., 2012). 
 
 The pathogenesis of leukemia arises from malignant transformation of 
hematopoietic precursor cells (Lutterbach, 2000) and associated with deregulation of 
transcription factors (Pandolfi, 2001), resulting in disruption of stem cell 
differentiation and cell proliferation (Look, 1997; Steffen et al., 2005; Tenen, 2003; 
Warner et al., 2004). The disruption may alter the normal physiological properties of 
the cells that include cell cycle control, programmed cell death (apoptosis) and DNA 
repair (Hiddemanna et al., 2005; Lutterbach, 2000). Since the alteration of apoptosis 
is mostly seen in all cancer types especially in leukemia (Accordi et al., 2010; 
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Heidari et al., 2010; Wemeau et al., 2010) and carcinoma (Bhatnagar et al., 2010), 
many cytotoxic drugs targeting this mechanism have gained prominence in medical 
oncology (Esposti 2010; Reis et al., 2010; Rigaud et al., 2010).  The examples of 
common chemotherapeutic drugs for acute myeloid leukemia (AML) include 
nucleoside analogs  (cytosine arabinoside [Ara-C]) and anthracyclines (idarubicin, 
daunorubicin). These drugs inhibit the proliferation of cancer cells through the 
impairment of DNA replication and induction of apoptosis (Guzman et al., 2005). 
Previous studies have reported on the mechanism of other conventional cytotoxic 
drug, all-trans retinoic acid (ATRA) that is used as a treatment for acute 
promyelocytic leukemia. The mechanism of ATRA is mainly through the activation 
of ubiquitin-proteosome and caspase system, leading to the induction of apoptosis 
(Nervi et al., 1998; Zhu et al., 1999). In addition, a study conducted by Liu et al. 
(2000) has revealed 169 genes modulated by ATRA that are involved in various 
signaling pathways including cell cycle regulation and apoptosis.  
  
However, one downside of conventional cancer therapies is the side effects. 
Although modern chemotherapy results in very high remission induction rates, yet 
there are many cases of patients experiencing relapse after receiving chemotherapy. 
For instance, the chemotherapy performed on acute lymphocytic leukemia (ALL) 
patients usually gives successful recovery rates but almost 25% of children and 70% 
of adult experienced relapse after the treatment (Rezaei et al. 2012). This may be due 
to the quiescent state of leukemic stem cells (LSCs), allowing some of the malignant 
stem cells to be resistant towards the standard chemotherapy and eventually 
contribute to relapse (Guzman et al., 2005). Moreover, although these drugs are used 
to target tumour cells, most of them can also induce genotoxic, carcinogenic and 
! 3 
teratogenic effects in non-tumour cells (Chung et al., 1998; Philip 2005). These side 
effects limit the application of chemotherapeutic agents despite their high efficacy in 
the killing of target malignant cells.  
 
Hence, the search for alternative or complementary drugs that are effective on 
cancer cells through the induction of apoptosis while showing minimal toxicity to 
normal cells and/or benefit the immune response is an active area of research 
(Alonso-Castro et al., 2012). Many of these investigations involve plant-based, 
folkloric medicine from various societies around over the world. A report from 
World Health Organisation (WHO, 1996) stated that about 80% of the world 
population is wholly or partially dependent on plant-based therapies. Moreover, a 
previous report stated that around two thirds of current medicines are derived from 
plants, or are synthetics derived from lead compounds discovered in plants 
(Rollinger, Langer, & Stuppner, 2006).  
 
  One of the intensively investigated medicinal plants is Catharanthus roseus 
(C.roseus) (L) G. Don, formerly Vinca rosea L. (Apocynaceae) that is commonly 
known as Madagascar periwinkle. It belongs to a taxonomical group of plants that 
contains more than 130 different pharmacologically active terpenoid indole alkaloids 
(TIAs) (Blasko & Cordell, 1990; Costa et al., 2008). Several authors reported how 
this medicinal plant is highly consumed, worldwide, by means of decocts and 
infusions for various applications, such as diabetes mellitus, rheumatism, fever or 
arrest of bleeding. The hot water extracts of the roots are also used for the treatment 
of stomach problems, heart diseases and as antigalactagogue and cholagogue agent 
(Ross, 2003). In addition, the leaves of this species are also chewed, in some places, 
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as a way to suppress the sensations of hunger and fatigue (van der Heijden et al., 
2004). The anticancer alkaloids present in this plant namely vinblastine and 
vincristine have been proven to induce mechanism of apoptosis through caspase-3 
activation (Berry et al., 2001). Previous studies showed that the induction of 
apoptosis initiated by these compounds are associated with cell cycle arrest, 
particularly metaphase arrest by vinblastine (Berry et al., 2001) and G2/M phase 
arrest by vincristine (Wang et al., 1998). These alkaloids achieved a very important 
role for the treatment of Hodgkin’s and non-Hodgkins’s lymphomas, acute 
lymphoblastic leukaemia, neuroblastoma and breast carcinoma (Dong et al., 1995). 
As the induction of apoptosis is a highly desirable goal of strategy for cancer control, 
it is thus important to evaluate potential apoptotic inducer from plants, either in the 
form of crude extracts or as isolated compounds (Taraphdar et al., 2001).  
 
However, the problem arises from vinblastine and vincristine is the toxicity 
effects. These two alkaloids have similarity in structure, only the substitution of a 
formyl group for a methyl group in vincristine, in comparison with vinblastine. The 
dose-limiting toxicity for vincristine is neurotoxicity while bone marrow toxicity 
limits the use of vinblastine (Lobert, Ingram & Correia, 1999). Even though many 
further studies have been conducted to reduce the toxicity effects through the 
modification of their structure and production of analogues of vinblastine and 
vincristine (Ishikawa et al., 2009; Kuboyama et al., 2004), yet the safety effects on 
normal cells remain unclear. Therefore, the study of the safety sides of C.roseus 
extract is getting more important. Moreover, only few data are available that reported 
the effects of this extract on normal cells. Differential effects of the extract between 
cancer cells and normal cells could lead to innovative strategies in cancer control. To 
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study new therapeutic immunomodulatory approaches, in present study, the 
cytotoxicity effects of crude C.roseus aqueous extract were compared between 
leukemic Jurkat T-cell line and normal peripheral blood mononuclear cells 
(PBMCs). Investigation of the cell proliferation effect of the natural product on 
normal immune cells is considered as a preliminary study for the discovery of new 
immunomodulator from herbs, and human PBMCs is commonly used as a target cell 
for this study (Kumar et al., 2004; Swamy & Tan, 2000). Thus, an investigation of 
cytotoxicity effects on normal PBMCs may expand the knowledge of the possible 
biological effects of this crude extract consumed in folkloric medicine. 
 
1.2 Objectives of the Study 
 The C.roseus aqueous extract that were usually prepared by decoction or hot 
water extract has been historically used to treat a wide assortment of diseases in 
various developed and developing countries. Ironically, only few scientific reviews 
reported on the effects of this crude aqueous extract on cells, especially on the 
normal cells. The objectives of the present study are as follow: 
1. To quantify concentration of vinblastine, one of the anticancer 
compounds in C.roseus aqueous extract 
2. To compare the growth inhibitory effects of the C.roseus aqueous extract 
on normal PBMCs and Jurkat cells 
3. To identify the type of cell death in C.roseus-treated Jurkat cells 
4. To determine the proliferation of T-helper (CD4+) and T-cytotoxic 
(CD8+) cells in C.roseus-treated PBMCs 
5. To evaluate the effects of the C.roseus aqueous extract on the production 
of immunoglobulins and complements 
! 6 
6. To screen the differential expression of genes in C.roseus-treated Jurkat 
cells associated with apoptosis and cell cycle progression 
! !! 7!
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Cancer Surveillance  
 Carcinogenesis implies adaptation of cancer cells to an adverse environment. 
The immune surveillance hypothesis originally describes the ability of the immune 
system to recognize and destroy malignant cells. However, in certain circumstances, 
the cancer cells are capable to modify the immune system to avoid destruction 
(Tham & Abastado, 2011). Further discoveries on immune surveillance led to the 
formation of a concept of “cancer immunoediting” that further clarified the 
hypothesis of cancer immunosurveillance. Three distinct stages of cancer 
immunoediting include elimination, equilibrium and escape (Dunn, Fecci & Curry, 
2012), as shown in Figure 2.1. 
 
 
Figure 2.1. Phases involved in immunoediting. Taken from “Escape of tumor 
immune surveillance and metastasis” by M. Tham and J.P. Abastado (2012). Drug 
Discovery Today: Disease Models, 8(2-3), p. 82. 
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2.1.1 Elimination 
 In this phase, tumor-specific antigens trigger innate and adaptive immune 
response, which leads to the destruction and early dissemination of cancer cells, 
especially high immunogenic cancer cells (Figure 2.1). Infiltration of immune cells 
into tumors is a well-documented observation especially in solid tumors (Chowa, 
Mollerb & Smytha, 2012). There are many mechanisms involved to eliminate the 
cancer cells, for instance the recognition of stress-induced ligands by lymphocyte 
activation receptor will alert the neighboring cells to early transformation (Guerra et 
al., 2008). Another mechanism can be through the release of danger signals by either 
transformed or dying tumor cells that will initiate an activation of immune system 
(Sims et al., 2009). On the other hand, in the absence of signals, the early 
transformed cancer cells could not be recognized by the immune cells and will enter 
the next phase called equilibrium phase.  
 
2.1.2 Equilibrium 
 The equilibrium phase is defined as a latent period in cancer development in 
which the survived cancer cells persist in a dynamic interaction with immunity 
within the cancer microenvironment (Dunn et al, 2012). Koebel et al. (2007) showed 
that when a low dose of carcinogen MCA administered into immunocompetent mice, 
small masses were formed at the injection site at a long-term period of time. 
Meanwhile, when the carcinogen MCA administered into immunocompetent mice 
with absence of either T cells or IFN, the masses were formed rapidly. The 
equilibrium phase involves immune selection pressure resulting a formation of tumor 
cells with reduced immunogenicity. Since equilibrium phase is a continuous process 
between elimination of tumor cells and emergence of resistant tumor cells, thus this 
phase is considered as the longest phase in immunoediting (Chowa, 2012). The 
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cancer cells survive in equilibrium phase by reducing their immunogenicity and/or 
induce immunosuppression. The cellular components of immune system affected by 
reduced immunogenicity and immunosuppression include Natural Killer (NK) cells, 
macrophages, CD8+ T- cells and CD4+ T- cells, as shown in Figure 2.1. It has been 
shown that in CD8-depleted animals, the pathological examination of their lungs 
revealed a higher number of proliferating cancer cells, suggesting CD8+ cells control 
metastatic dormancy through its secretion of cytostatic cytokines and direct 
cytotoxicity that will inhibit the proliferation of cancer cells. In this phase, the 
number of immunosuppressive and poorly immunogenic cancer cells begins to 
accumulate (Tham & Abastado, 2011). Overall, there are three possibilities of 
outcomes as a result of the interaction between the tumor cells and immunity which 
are; 1) the tumor cells may persist in this phase without progression, 2) the tumor 
cells may outstrip immune pressure, 3) the tumor cells may be clinically manifested 
in escape phase (Dunn et al, 2012). 
 
2.1.3 Escape 
 In this phase, the tumor cells progress and overcome the host through either 
intrinsic or extrinsic changes. Intrinsic changes occur at tumor cell level by reducing 
the ability of a tumor cell to be recognized or killed, whereas extrinsic changes 
involve the microenvironment by attenuating the effector capacity of the immune 
system (Dunn et al., 2012). Reduction of immunogenicity such as loss of major 
histocompatibility complex (MHC) class I protein of tumor cells can lower immune 
recognition by tumor-specific T cells or other recognition pathways. Additionally, an 
expression of anti-apoptotic molecules may cause the tumor cells become resistant to 
immune system, allowing them to survive. On the other hand, a complex 
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immunosuppressive network within the tumor environment creates a crosstalk 
between the environment and tumor cells. One of the possible mechanisms that lead 
to immunosuppressive is the release of several factors from immune cells such as 
vascular endothelial growth factor (VEGF), transforming growth factor (TGF), 
prostaglandin E2 and interleukin-10 (IL-10) (Chow et al., 2012), as shown in Figure 
2.1. 
 
2.2 Plant-derived Anticancer Compounds 
 The application of plants has proved to be an important natural source to 
develop an effective anticancer therapy for several years. Approximately 30 
compounds that are derived from plant have been successfully isolated and are 
currently under clinical trials (Nirmala, Samundeeswari & Sankar, 2011). The 
secondary metabolites have proved to be an excellent reservoir of new medical 
compounds from various types of plant for examples, Catharanthus roseus, 
Podophyllum species, Taxus brevifolia, Camptotheca acuminate, Betula alba, 
Cephalotaxus species, Erythroxylum pervillei, Curcuma longa, Ipomoeca batatas 
and Centaurea schischkinii (Davis & Kuttan, 2000). According to Nirmala et al. 
(2011), the major plant-derived anticancerous compounds has been classified into 
four: 1) vinca alkaloids; 2) epipodophyllatoxin lignans; 3) taxane diterpenoids and 4) 
camptothecin quinolone alkaloid derivatives. 
 
2.2.1 Major Groups of Natural Anticancer Compounds 
 Vinca alkaloids are the most important class of anticancer drugs. The 
mechanism of action includes the inhibition of cell proliferation through mitotic 
arrest that eventually leads to the mechanism of programmed cell death, apoptosis. 
The major naturally occurring active anticancer compounds are known as vinblastine 
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and vincristine also present in the C.roseus. The effectiveness of these compounds 
has been developed by producing semi-synthetic analogues such as vinorelbine and 
vindesine. These novel vinca alkaloids are currently under phase II clinical trials 
(Okouneva et al., 2003; Simeons et al., 2008).  
 
The second group of anticancer compounds, which is known as 
podophyllatoxin, comprises of compounds isolated from Podophyllum species. So 
far, there were two semi-synthetic analogs derived from the isomer of 
podophyllatoxin, Epipodophyllotoxin namely Etoposide and Teniposide. These two 
semi-synthetic compounds are believed to exhibit effective effects for the treatment 
of lymphomas, bronchial and testicular cancers (Shoeb, 2006).  
 
The third group is known as taxanes and the major compounds are known as 
paclitaxel (Taxol®) and Docetaxel (Taxotere®). Paclitaxel is the major compound 
extracted from the bark of the Pacific Yew, Taxus brevifolia Nutt. (Taxaceae) while 
the Docetaxel is the semi-synthetic derivative of paclitaxel (Nirmala et al., 2011). 
Many previous reports have emphasized that these compounds are well known as an 
effective microtubule inhibitor for cancer chemotherapy. Moreover, these drugs are 
usually applied for the treatment of ovarian cancers, squamous cancers of the head 
and neck, as well as for non-small cell lung cancer, small-cell lung cancer, and other 
types of cancers (Singla, Garg & Aggarwal 2002).  
 
Another major group of natural compounds used in cancer chemotherapy is 
camptothecin extracted from the barks and stem of the Chinese ornamental tree, 
Camptotheca acuminate. The analogues of this compound were previously produced 
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due to the poor solubility and severe toxicity effects of camptothecin. The examples 
of the analoques include topotecan, irinotecan, 9-aminocamptothecin, lurtotecan and 
rubitecan. The anticancer mechanism of these compounds is through the inhibition of 
DNA Topoisomerase I leading to the disruption of the DNA functions and 
transcription (Srivastava et al., 2005). 
 
 Many other plant-derived anticancer compounds also have anticancer 
properties through various mechanisms, for instance, berbamine that was isolated 
from Berberis amarensis and usually used for the treatment of chronic myeloid 
leukemia. This compound inhibited the proliferation of cancer cells via caspase-3-
dependent apoptosis (Kim et al., 2007). Other active compounds that also act through 
the induction of apoptosis are Silvestrol that was derived from Aglaia foveolata 
(Kinghom et al., 2009) has been used for prostate, breast and lung cancers while 
PG490-88 from Tripterygium wilfordii (Liu et al., 2011) is widely used to treat 
prostate cancer.  
 
2.2.2 Catharanthus roseus 
 This plant is commonly known as periwinkle or kemunting cina (in Malay) 
and belongs to Apocynaceae family. This plant belongs to a small genus of 8 species 
and most of the species originate from Madagascar. Figure 2.2 illustrates the various 
species of C.roseus plant. The Madagascar periwinkle has been cultivated as an 
ornament throughout the tropics and occasionally in the subtropics. This plant can be  
characterized by an erect or decumbent, deciduous undershrub that can grow 
between 30 to 200 cm height and usually with white latex. The length of the roots is 
usually up to 70 cm long while the stems are often woody at base. The leaves are  
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Figure 2.2. Various species of Madagascar periwinkle C.roseus. Taken from “Know 
the medical herb: Catharanthus roseus (Vinca rosea)” by K. Y. Loh (2008). 
Malaysian Family Physician, 3(2), p. 123. 
 
 
decussate, glossy, elliptical to obovate or narrowly obovate, wedge-shaped while the 
colour of the leaves are dark green (Aslam et al., 2010; Padua et al., 1999). Some of 
the leaves are oblique at base, apex is obtuse or acute with a mucronate tip. 
Meanwhile, the flowers are actinomorphic, bisexual, 5-merous and subsessile. The 
sepals are slightly connate at base and green in colour. Meanwhile, the petal is 
salver-shaped, and the colour of the petal can vary, including pink, rose-purple or 
white with a purple, red, pink, pale yellow or white centre with tube 2-3 cm long and 
widening near the top (Padua et al., 1999). !
  C. roseus is synonym with its characteristic alkaloids (Pereira et al., 2010). 
Even though it has been reported that this plant contains more than 130 alkaloids, 
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only some of these are commercially available such as serpentine, ajmalicine, 
vincristine and 3’, 4’-anhydrovinblastine. The first two alkaloids are prescribed for 
antihypertensive and another report has mentioned that serpentine also has been used 
as sedative. The vinblastine (vincaleucoblastine) and vincristine (leucristine) are 
commonly used as anticancer for various types of cancers (van der Heijden et al., 
2004). Aslam et al. (2010) reported that vinblastine sulphate with its brand drug 
name Velban has been used for the treatment of Hodgkin’s disease, lymphocarcoma, 
choriocarcinoma, neuroblastoma, breast carcinoma, lungs and other organs in acute 
and chronic leukemia while vincristine sulphate with its brand drug name, Oncovin 
has been scientifically proven can treat acute leukaemia in children, Hodgkin’s 
disease, Wilkins’s tumor, neuroblastoma and reticulum cell sarcoma. Vinblastine and 
vincristine are known as secondary metabolites and considered as the end products of 
this plant extract.  
 
 Moreover, the production of the vinblastine and vincristine is still dependent 
on the wild type plant because they remain impossible to be synthesized in vitro 
(Exposito et al., 2009). These alkaloids are shown to be tissue-specific, which require 
both aerial and root parts of a plant to be synthesized (De Luca & Laflamme, 2001). 
The yield of the compounds extracted from the plant is usually very low and 
therefore, difficult for purification. These limitations make the compounds become 
highly valuable and expensive (Costa et al., 2008; Fett-Neto, DiCosmo, Reynolds, & 
Sakata, 1992; Noble, 1990). This is due to the complexity and unique bisindole 
alkaloid structure, which are difficult to produce synthetically. Previous study 
reported that this is partly due to the difficulty to obtain correct conformation of 
stereogenic centers, which are crucially important for their activity. For instance, in 
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vincristine the configuration at the C-16′ stereogenic centre is S while at C-14′ it is R 
and S at C-20′. The inversion of C-16 configuration from S to R results in a complete 
loss of activity as does the C-14′ conversion from R to S (Kuehne & Marko, 1990). 
The chemical structures of the major active compounds are illustrated in Figure 2.3. 
 
 
 
Figure 2.3. The chemical structures of selected terpenoid indole alkaloids derived 
from C.roseus plant. Ajmalicine (1) used as antihypertensive agent, serpentine (2) 
dor sedative, vinblastine (3) and vincristine (4) used as anticancer agents. Adapted 
from “Rapid Identification of Enzyme Variants for Reengineered Alkaloid 
Biosynthesis in Periwinkle” by P. Bernhardt, E. McCoy and S. E. O’Connor, 2007, 
Chemistry & Biology, 14, p889. 
 
 Apart from the clinical application of some important alkaloids in C.roseus 
plant, the medicinal purposes of its wide application as a folk remedy should be 
highlighted. The extracts are usually prepared as a decoction or hot water extract of 
either the entire plant, leaves, roots or aerial parts (Aslam et al., 2010). An extensive 
study has previously summarized the traditional purposes of the extract, that vary in 
different countries, for example the hot water extract of C.roseus has been used for 
diabetes in Europe (Swanston-Flatt et al., 1989) while in India, the juice from the 
leaves was used to treat wasp stings (Farnsworth et al., 1961). However, there are not 
many scientific reviews that clearly emphasized the biological effects of the C.roseus 
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crude extract despite its wide applications as a worldwide folk remedy. The summary 
of the traditional medicinal purposes of the application of C.roseus aqueous extract 
that were consumed orally is as shown in Table 2.1.  
 
Table 2.1 
The Traditional Medicinal Purposes of Crude Aqueous Extract of C.roseus  
 
Country Method of preparation Traditional uses Citation 
Australia Hot water extract of 
dried leaves 
Menorrhagia, diabetes and 
extract of root bark is taken 
orally as febrifuge. 
Bhandari et al., 1959; 
Webb, 1984 
Brazil Hot water extract of 
the entire plant 
Diabetes mellitus. Brandao et al., 1985; 
De Mello, 1980 
China Hot water extract of 
the aerial parts 
Menstrual regulators. Fransworth, 1961; 
Virmani et al., 1978 
Cook Island Decoction of dried 
leaves 
Diabetes, hypertension and 
cancer 
Holdsworth, 1990 
Dominica Hot water extract of 
leaves 
Consumed by pregnant 
woman to combat primary 
inertia in childbirth, diabetes 
Hodge & Taylor, 1956 
England  Hot water extract of 
dried entire plant 
Diabetes Thompson, 1976 
Europe Decoction of dried 
leaves 
Diabetes Swanston-Flatt et al., 
1989 
France Hot water extract of 
dried leaves 
Antigalactagogue  Fransworth, 1961 
French Guina Hot water extract of 
dried leaves 
Cholagogue Luu, 1975 
India  Hot water extract of 
dried entire plant 
Cancer Virmani et al., 1978 
Jamaica Hot water extract of 
dried leaves 
Diabetes Morrison, 1982 
Kenya  Hot water extract of 
dried leaves 
Diabetes Morrison, 1982 
Mozambique Hot water extract of 
aerial parts 
Diabetes, rheumatism Amico, 1977 
North Vietnam Hot water extract of  Menstrual regulators Fransworth, 1961; 
Virmani et al., 1978 
Pakistan  Hot water extract of 
dried ovules 
Diabetes Atta-Ur-Rahman, 1982 
Peru Hot water extract of 
dried entire plant 
Cancers, heart disease and 
leishmaniasis 
Fransworth, 1961 
Philippines Hot water extract of 
root 
Consumed by pregnant 
women for abortion 
Virmani et al., 1978 
South Africa Hot water extract of 
dried leaves 
Menorrhagia and diabetes Bhandari et al., 1959; 
South Vietnam Hot water extract of 
entire plant 
Antigalactagogue Fransworth, 1961;  
Virmani et al., 1978 
Taiwan Decoction of dried 
entire plant 
Diabetes and liver diseases Fransworth, 1961 
Thailand Hot water extract 
dried entire plant 
Diabetes Yang et al., 1987 
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Country Method of preparation Traditional uses Citation 
Venda Hot water extract of 
dried root 
Venereal diseases Siegel, 1976 
West Indies Hot water extract of 
leafy stems 
Diabetes Nguywen, 1977 
Notes. Adapted and revised from “Catharanthus roseus (L.) G. Don. An Important 
Drug: Its Applications and Production” by J. Aslam, S. H. Khan, Z. H. Siddiqui, Z. 
Fatima, M. Maqsood, M. A. Bhat, S. A. Nasim, A. Ilah, I. Z. Ahmad, S. A. Khan, A. 
Mujib and M. P. Sharma, 2010, Pharmacie Globale, 4(12), p. 2. 
 
 
2.3 Mechanism of Cell Death 
 The balance between the rate of cell death and the rate of cell division ensure 
the integrity and physiological homeostasis of an organ. The mechanism of cell death 
is important to remove terminally injured or unwanted cells that utilize valuable 
substrates and nutrients (Coates et al., 2010).  
  
2.3.1  Type I Cell Death 
 Type I cell death is also known as apoptosis. The term Apoptosis is 
originated from Greek word (apo – from, ptosis – falling) (Kerr, Wylie & Currie, 
1972).  Apoptosis can be defined as a genetically programmed mechanism that 
allows the cell to commit suicide (Duprez et al. 2009; Fulda et al. 2010). Apoptosis is 
characterized with distinct biochemical and morphological features that play 
important roles in the maintenance of tissue development, homeostasis and 
regulation of immune responses. However, the interruption of this mechanism can 
lead to various disorders including cancer, autoimmune and neurodegenerative 
diseases. Therefore, the modulation of the cascade pathway of apoptosis is a 
potential therapeutic approach for the treatment of several human diseases (Agostini 
et al., 2011). 
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 Apoptosis has been further classified into two major well-studied pathways 
namely extrinsic or receptor-mediated pathway and intrinsic or mitochondria-
mediated pathway, as illustrated in Figure 2.4. The extrinsic pathway is initiated 
through an engagement between the death receptors present on the cell surface and 
their respective ligands (Scaffidi et al., 1998). The death receptors are from a sub-
group of Tumor Necrosis Factor receptors (TNFR) superfamily, for example TNF, 
CD95 (Fas) and TNF-related apoptosis inducing ligand (TRAIL) receptors. These 
tetrameric receptors have an extracellular domain to engage the ligands and an 
intracellular cytoplasmic domain that is also referred to death domain that is 
responsible for the death signal transmission (Scott et al., 2009). The signal is 
transmitted from the surface to the intracellular signaling pathways via an interaction 
between the death receptors and their specific ligands (Ashkenazi & Dixit, 1998). 
This interaction would further induce homotypical interactions of the death receptors 
with Fas-associated death domain (FADD) or with TNER-associated death domain 
(TRADD) of specific nuclear protein. As a result, a signal complex called death 
inducing signaling complex (DISC) is formed and activated leading to the 
recruitment and activation of initiator caspases, procaspase-8 and -10 (Green, 1998, 
2005; Portt et al., 2011). The caspase cascade is the most studied signaling pathway 
in apoptosis. Activated caspase 8 will subsequently activate downstream effector 
caspases, leading to the onset of apoptosis (Zhang et al., 2010). 
 
 The second apoptosis pathway is known as intrinsic or mitochondria-
mediated pathway (Figure 2.4). This pathway can be induced by receptor-
independent stimuli such as radiation, free radicals, viral infections and 
serum/growth factor withdrawal (Indran et al., 2011). Following the death trigger,  
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Figure 2.4. Apoptosis signaling pathways. The extrinsic pathway is initiated at the 
cellular membrane through the binding of death receptor ligands to their respective 
receptors while the intrinsic pathway involves the depletion of mitochondrial 
membrane potential and release of pro-apoptotic proteins such as cytochrome c, 
Smac/DIABLO (second mitochondria-derived activator of caspases). The black 
arrow indicates activation while the grey line indicates inhibition. Taken from 
“Targeting Apoptotic Pathway by Celecoxib in Cancer” by V. Jendrossek,  2011, 
Cancer Letters, p.3. 
 
the mitochondrial permeability transition pore open and cause the changes of the 
permeability in the inner part of the mitochondria (Hengatner, 2000). 
 
 The mitochondrial transmembrane potential is lost leading to the release of 
pro-apopotic proteins that can be classified into two categories. The first group 
comprises proteins that activate the caspase-dependent pathway. The examples of the 
proteins are cytochrome c and Smac/DIABLO (second mitochondria-derived 
activator of caspases). The cytochrome c induces oligomerization of Apaf-1 
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(apoptotic protease activating factor 1) and this activates the caspase 9. This 
mechanism further initiates the formation of apoptosome which consists of activated 
cytochrome c, Apaf-1 and caspase 9. An executioner caspases 3 and 7 are further 
activated and consequently, the cell dismantles through nuclear fragmentation 
(Hengatner, 2000; Gross et al., 1999; Slee et al., 1999). Apoptotic progression occurs 
as the protein of Smac/DIABLO binds to IAPs (inhibitor of apoptosis proteins) to 
deactivate them and thus, allowing the apoptosis to occur (Scaffidi et al., 1998). The 
second group of pro-apoptotic proteins consists of apoptosis inducing factor (AIF) 
and endonuclease G (Endo G). The release of these proteins has been reported to 
occur during late apoptosis and associated with the translocation of the proteins to 
the nucleus and DNA fragmentation. Unlike the first group of proteins, the apoptosis 
mechanism initiated by the second group of pro-apoptotic proteins is caspase-
independent (Joza et al., 2001).  
  
 Morphologically, apoptotic cells are characterized by chromatin 
condensation, cleavage of chromosomal DNA into internucleosomal fragments, cell 
shrinkage, membrane blebbing, formation of apoptotic bodies with plasma 
membrane breakdown, phospatidylserine (PS) externalization to the outer leaflet of 
outer membrane, followed by ordered removal by phagocytes (Luthi & Martin, 
2007). A typical distinct morphological feature of apoptotic cells is a cleavage of 
DNA into fragments with a size of 180-200 bp (Compton, 1992).  
 
(a) Apoptotic-regulated Proteins 
 The mechanism of apoptosis can be regulated by several factors. Apart from 
the proteins that directly take part as components in the apoptotic pathway such as 
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death receptors, adaptor proteins, kinases and caspases, the well-known and major 
regulator is Bcl-2 family that includes at least 20 proteins and share between one and 
four conserved regions, designated “Bcl-2 homology domains” (BH) (Kuroda & 
Taniwaki, 2009; Willis et al., 2007). A study reported by Kuroda and Taniwaki 
(2009) has further broadened the groups into BH1-4, BH1-3 (Bax/Bak-like proteins), 
BH2-3, BH3-4, and BH-3 only proteins. The proteins that carry these domains have 
been further classified into pro- and anti-apoptotic, as shown in Figure 2.5.  
 
 All the anti-apoptotic members, which are Bcl-2, Bcl-XL, Bcl-w, A1 and Bcl-
B carry four regions of the BH domains except for Mcl-1 that has three regions. 
Additionally, the pro-apoptotic proteins, the Bax/Bak-like proteins include Bax, Bak, 
and Bok with three BH domains whereas BH-3 only proteins consist of Bim (Bcl-2-
interacting mediator of cell death, also known as Bod), Bad (Bcl-2-antagonist of cell 
death), Bik (Bcl-2-interacting killer, also known as Nbk or Blk), Bid (BH3-
interacting domain death agonist), Hrk (Harakiri, also known as DP5), Noxa, Puma 
(p53-upregulated modulator of apoptosis, also known as Bbc3) and Bmf (Bcl- 2 
modifying factor). The pro-apoptotic members with different groups are activated by 
different death stimuli and capable of neutralizing the anti-apoptotic proteins (Cory 
& Adams, 2002; Huang & Strasser, 2000).  
 
  A previous study has shown that Bcl-2 and Bcl-XL protect the cells by 
interacting with mitochondrial proteins, for instance adenine nucleotide translocase 
(ANT) and voltage dependent anion channel (VDAC). As a result, mitochondrial 
pores formation is inhibited, thus protecting membrane integrity and inhibiting 
release of cytochrome c. Bax, a pro-apoptotic protein is located in the cytosol.  
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Figure 2.5. List of anti-apoptotic and pro-apoptotic members of Bcl-2 protein family. 
Taken from “Involvement of BH3-only Proteins in Hematologic Malignancies” by J. 
Kuroda and M. Taniwaki, 2009, Critical Reviews in Oncology/Hematology, 71, p. 
90. 
 
Following the death trigger, this protein will translocate to the mitochondria and 
interact with other pro-apoptotic proteins such as Bak or truncated Bid. Thus, 
mitochondrial pores are formed, eventually leading to the release of cytochrome c 
(Czabotar et al., 2007). Some studies have shown that Bax protein can also 
interactwith ANT and/or VDAC to induce the mitochondrial permeability and the 
formation of pores (Marzo et al., 1998). Another pro-apoptotic protein Bak localizes 
at the outer membrane of mitochondria and endoplasmic reticulum. The activity of 
these apoptotic proteins can be inhibited via their binding with anti-apoptotic Bcl-2 
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family members (Czabotar et al., 2007; Huang & Strasser, 2000; Puthalakath & 
Strasser, 2002). 
 
 However, a previous study suggested that the pathways can be linked and the 
molecules involved can affect the others in another pathway (Daniel & Korsmeyer, 
2004). Moreover, many recent evidences have shown greater complexity and 
diversity in each pathway and enable to cross-activate to not only intrinsic or 
extrinsic pathway but also necrotic sub-pathways (Duprez et al., 2009; Whelan, 
Kaplinsky & Kitsis, 2010).  
 
(b) Apoptosis and Cancer 
 In cancer, the malignant transformation of cells involves a complex multi-
step process, allowing the cells to protect themselves from the mechanism of 
apoptosis (Coates et al., 2010). Consequently, the cells can survive against various 
adverse events such as metabolic stress, oncogene activation, nutrient and growth 
factor depletion, lack of blood supply, hypoxia and therapeutic intervention 
(Folkman, 2003; Mathew et al., 2007). Thus, many research have been done that 
target the mechanisms of cancer progression (Indran et al., 2011). 
 
 The most common factor causing the inhibition of apoptosis in human cancer 
cells is the loss or inactivation of tumour suppressor p53. This is followed by other 
factors such as, the inactivation of the apoptosome-mediated pathways and defect in 
the components of apoptotic machinery like APAF-1 and caspase-9 (Soengas et al., 
1999). Loss of p53 function has been shown contribute to the instability of 
mitochondrial genome resulting to an increase level of cellular ROS and thus will 
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distract the mitochondrial-dependent apoptotic pathway (Brandon et al., 2006; Chen 
et al., 2010; Pani, Koch & Galeotti, 2009). Moreover, mutations or altered expression 
of p53 downstream effectors such as Bax, Bak and APAF-1 or upstream regulators 
such as ATM and Mdm 2 have also been reported in many types of cancer. 
Therefore, mutant p53 is always associated with resistance to standard chemotherapy 
as it blocks the mechanism of apoptosis induced by the chemotherapeutic agents 
(Ekert et al., 2004). Meanwhile, the inactivation of the apoptosome-mediated 
pathways were previously reported to occur in human cancer cells, including 
malignant melanoma, ovarian cancer, leukemia, and non-small cell lung carcinoma  
(Wolf et al., 2001).  
 
 Additionally, the roles of IAPs that are selectively overexpressed in various 
types of cancers will also lead to the defect in apoptotic pathways and have been 
shown in previous study (Nachmias, Ashhab & Ben-Yehuda, 2004). They proposed 
an effective therapeutic target by specifically inhibiting the IAPs through cell-
permeable Smac peptides, leading to the inhibition of its binding to caspase. This 
may sensitize the cancer cells to chemotherapy both in vitro and in vivo (Fulda et al., 
2002) 
 
2.3.2  Type II Cell Death 
 This type of cell death refers to a process called autophagy. It is a 
fundamental cellular homeostatic mechanism, whereby cells autodigest parts of their 
cytoplasm for removal or turnover. The examples include cell injury and 
accumulation of aggregated proteins, damaged organelles or membranes and 
intracellular parasites (Mathew et al., 2007; Mizushima et al., 2008). This 
mechanism has the ability to recycle old components into new building blocks that 
